CLEVELAND--(BUSINESS WIRE)--PGxHealth, a division of Clinical Data, Inc. (NASDAQ: CLDA), today announced the launch of a genetic test for electrical heart diseases that can be used by Medical Examiners or other licensed physicians for autopsy-negative cases of sudden unexplained death and sudden infant death syndrome. The introduction of the FAMILION® Postmortem Channelopathies Test at the National Association of Medical Examiners (NAME) meeting, October 1-6, 2010, in Cleveland, OH, marks the fourth significant genetic test launched by PGxHealth over the past 12 months with several more test launches expected this year. With the launch of the postmortem test, PGxHealth now offers nine FAMILION tests, and continues to lead the industry with the most comprehensive menu of genetic tests to diagnose or confirm familial heart diseases.
